SCHEMBL1154531

SCHEMBL1154531

CCOC(=O)Cc1ccc(OC)cc1-c1cccc(F)c1C#N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.43
KDM4E B2RXH2 7/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
BRD4 O60885 1/20 0.40
POLQ O75417 1/20 0.39
MAPT P10636 5/20 0.39
THRB P10828 1/20 0.39
ALDH1A1 P00352 8/20 0.39
NPC1 O15118 1/20 0.39
USP2 O75604 1/20 0.39
NFKB1 P19838 1/20 0.39
CASP1 P29466 1/20 0.39
RAB9A P51151 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPK1 P28482 2/20 0.38
L3MBTL1 Q9Y468 4/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1155129 0.87 HSD17B10 (0.45) KDM4EPOLQMAPTHSD17B10POLB
SCHEMBL1154380 0.85 TDP1 (0.43) KDM4EKMT2APOLQALDH1A1HSD17B10
SCHEMBL14334712 0.76 RAB9A (0.43) KDM4EMEN1KMT2APOLQMAPT
SCHEMBL1154947 0.74 PTGS2 (0.46) PPARGKMT2APOLQMAPTALDH1A1
SCHEMBL14334814 0.74 CD274 (0.43) KDM4EMEN1KMT2APOLQMAPT
SCHEMBL12400240 0.73 KDM4E (0.52) PPARGKDM4EMEN1KMT2AMAPT
SCHEMBL21437412 0.72 POLB (0.59) PPARGALDH1A1NPC1RAB9AHSD17B10
SCHEMBL29591243 0.72 POLB (0.59) PPARGALDH1A1NPC1RAB9AHSD17B10
SCHEMBL12093646 0.71 PPARG (0.48) PPARGKDM4EMEN1KMT2AMAPT
SCHEMBL21455751 0.70 ALDH1A1 (0.53) PPARGKDM4EMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3121176-A1 2,4-DIAMINOQUINAZOLINES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY Families of Spinal Muscular Atrophy (US) 2017-01-25 EP disclosed
EP-1765810-B1 2,4-DIAMINOQUINAZOLINES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY FAMILIES OF SPINAL MUSCULAR ATROPHY (US) 2016-08-17 EP disclosed
EP-2514748-B1 2,4-diaminoquinazolines for spinal muscular atrophy FAMILIES OF SPINAL MUSCULAR ATROPHY (US) 2016-08-10 EP disclosed
EP-2514748-A1 2,4-diaminoquinazolines for spinal muscular atrophy Families of Spinal Muscular Atrophy (US) 2012-10-24 EP disclosed
US-7888366-B2 2,4-diaminoquinazolines for spinal muscular atrophy FAMILIES OF SPINAL MUSCULAR ATROPHY (US) 2011-02-15 US disclosed
EP-1765810-A1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY Decode Chemistry, Inc. (US) 2007-03-28 EP disclosed
WO-2005123724-A1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY DECODE CHEMISTRY, INC. (US) 2005-12-29 WO disclosed
US-20050288314-A1 2,4-diaminoquinazolines for spinal muscular atrophy DECODE CHEMISTRY, INC. (US) 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288314-A1 2,4-diaminoquinazolines for spinal muscular atrophy SMN1; SMN2, MUSK, MYO3B PPARG 3776/4885KDM4E 214/4885MEN1 2282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.